ArticleMedChemComm2018
Artificial Macrocycles as IL-17A/IL-17RA Antagonists.
Article in MedChemComm, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Computational Identification of IL-17 a Small-Molecule Inhibitors as Potential Therapeutics for Plaque Psoriasis Through e-Pharmacophore Screening, Molecular Docking, and Molecular Dynamics Simulation.The protein journal · 2026Article
- Novel Macrocyclic Compounds Targeting STING for Autoimmune Diseases Treatment.ACS medicinal chemistry letters · 2026Article
- Article
- CytoSIP: an annotated structural atlas for interactions involving cytokines or cytokine receptors.Communications biology · 2024Article
- It's ok to be outnumbered - sub-stoichiometric modulation of homomeric protein complexes.RSC medicinal chemistry · 2023Review
- Multicomponent Macrocyclic IL-17a Modifier.ACS medicinal chemistry letters · 2022Article
- How RNA modifications regulate the antiviral response.Immunological reviews · 2021Review
- Benchmark of Generic Shapes for Macrocycles.Journal of chemical information and modeling · 2020Article
- Conformation of the Macrocyclic Drug Lorlatinib in Polar and Nonpolar Environments: A MD Simulation and NMR Study.ACS omega · 2019Article
- Artificial Macrocycles.Synlett : accounts and rapid communications in synthetic organic chemistry · 2018Article
- Artificial Macrocycles by Ugi Reaction and Passerini Ring Closure.The Journal of organic chemistry · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Interleukin 17(A) is a pro-inflammatory cytokine involved in several auto-immune and inflammatory diseases. Current antagonists against IL17(A) or its receptor (IL17R) that show efficacy in clinical trials are monoclonal-antibodies (mAbs). However, recently designed artificial macrocyles are potent IL17-IL17R antagonists. Based on Co-crystal structures, a better understanding the biological activity and SAR of the macrocycles has been elucidated, demonstrating that macrocycles can compete with mAbs for difficult targets such as PPIs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.